Longitudinal circulating tumor DNA analysis during treatment of locally advanced resectable gastric or gastroesophageal junction adenocarcinoma: the PLAGAST prospective biomarker study

Abstract excerpt

Patients with locally advanced resectable (LAR) gastric/gastroesophageal junction (G/GEJ) adenocarcinomas have a high recurrence risk despite pre- and post-operative treatment. In the PLAGAST prospective study (NCT02674373), we investigated the ability of circulating tumor DNA (ctDNA) to predict treatment response and improve risk stratification. Plasma samples were prospectively collected before neoadjuvant...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Esophageal Cancer Research and Treatment
• Share to Gastric Cancer Management and Outcomes
• Share to Gastrointestinal Tumor Research and Treatment